GlobeNewswire Inc | Jan 4, 2021 07:00AM EST

January 04, 2021

DURHAM, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS genome editing platform, today announced that Matt Kane, Co-founder and Chief Executive Officer and Derek Jantz, Ph.D., Co-Founder and Chief Scientific Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference taking place virtually from January 11-14, 2021.

Details for the company presentation are as follows:

39th Annual J.P. Morgan Healthcare ConferenceDate: Wednesday, January 13, 2021Time: 2:00 - 2:40 p.m. ET

A live webcast of the presentation will be accessible on the Companys website, www.precisionbiosciences.com, in the Investors & Media section under Events and Presentations. An archived replay of the webcasts will be available for approximately 30 days following the presentations.

About Precision BioSciences, Inc.Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Companys pipeline consists of multiple off-the-shelf CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

Investor Contact:Alex KellyInterim Chief Financial OfficerAlex.Kelly@precisionbiosciences.com

Media Contact:Maurissa MessierSenior Director, Corporate Communications Maurissa.Messier@precisionbiosciences.com